Related Experiment Videos
[Aggressive therapy of highly active systemic lupus erythematosus]
1Klinischen Abteilung für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien.
Acta Medica Austriaca
|January 1, 1996
Summary
Systemic lupus erythematosus (SLE) exacerbations are dangerous, requiring immunosuppression. While cyclophosphamide and corticosteroids are standard, immunoabsorption offers benefits in critical cases, balancing risks and benefits for long-term SLE management.
Area of Science:
- Rheumatology
- Immunology
Context:
- Life-threatening exacerbations of systemic lupus erythematosus (SLE) pose significant risks to vital organ function.
- Management of severe SLE flares necessitates aggressive immunosuppressive therapies.
Purpose:
- To outline current and alternative therapeutic strategies for managing severe SLE exacerbations.
- To discuss the role of various immunosuppressive agents and immunoabsorption in SLE treatment.
Summary:
- High-dose corticosteroids and intravenous cyclophosphamide are established treatments for severe SLE.
- Plasmapheresis is less common, but selective immunoglobulin removal (immunoabsorption) shows promise in critical situations.
- Long-term SLE management must weigh the benefits of immunosuppression against risks like infections, neoplasia, and potential autoimmune recurrence.
Impact:
- Improved understanding of treatment options for severe SLE exacerbations.
- Highlights the potential of immunoabsorption as an adjunct therapy in life-threatening SLE cases.
- Emphasizes the critical balance between managing SLE activity and mitigating long-term treatment side effects.